Literature DB >> 22166638

Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.

Shan-Juan Fang1, Xue-Si Wu, Zhi-Hong Han, Xiao-Xia Zhang, Chun-Mei Wang, Xin-Yan Li, Ling-Qiao Lu, Jing-Lan Zhang.   

Abstract

BACKGROUND: Neuregulin-1 (NRG-1), the ligand of the myocardial ErbB receptor, is a protein mediator with regulatory actions in the heart. This study investigated whether NRG-1 preconditioning has protective effects on myocardial ischemia/reperfusion (I/R) injury and its potential mechanism.
METHODS: We worked with an in vivo rat model with induced myocardial ischemia (45 minutes) followed by reperfusion (3 hours). NRG-1 message was detected in the heart using RT-PCR and the protein levels of NRG-1 and ErbB4 were detected by Western blotting analysis. Infarct size was assessed using the staining agent triphenyltetrazolium chloride and cardiac function was continuously monitored. The levels of creatine kinase and lactate dehydrogenase in plasma were analyzed to assess the degree of cardiac injury. The extent of cardiac apoptosis was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and by Western blotting analysis of cleaved caspase-3. We examined the phosphorylation of Akt in the myocardium and the effect of PI3K/Akt inhibition on NRG-1-induced cardioprotection.
RESULTS: Transcription and expression of NRG-1 and phosphorylation of its ErbB4 receptor were significantly upregulated in the I/R hearts. NRG-1 pretreatment reduced the infarct size following cardiac I/R in a concentration-dependent manner with an optimal concentration of 4 µg/kg in vivo. NRG-1 pretreatment with 4 µg/kg, i.v. markedly reduced the plasma creatine kinase and lactate dehydrogenase levels. Pretreatment with NRG-1 also significantly reduced the percentage of TUNEL positive myocytes and the level of cleaved caspase-3 in the I/R hearts. Pretreatment with NRG-1 significantly increased phosphorylation of Akt following I/R. Furthermore, the cardioprotective effect limiting the infarct size that was induced by NRG-1 was abolished by co-administration of the PI3K inhibitor LY294002.
CONCLUSIONS: The concentration of NRG-1, a new autacoid, was rapidly upregulated after myocardial I/R. NRG-1 preconditioning has cardioprotective effects against I/R injury through a PI3K/Akt-dependent mechanism in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22166638

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  25 in total

1.  A specified therapeutic window for neuregulin-1 to regenerate neonatal heart muscle.

Authors:  Federica Santoro; Makoto Sahara
Journal:  Ann Transl Med       Date:  2015-10

Review 2.  The Role of MicroRNAs in the Cardiac Response to Exercise.

Authors:  Xiaojun Liu; Colin Platt; Anthony Rosenzweig
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

3.  4-Dimensional light-sheet microscopy to elucidate shear stress modulation of cardiac trabeculation.

Authors:  Juhyun Lee; Peng Fei; René R Sevag Packard; Hanul Kang; Hao Xu; Kyung In Baek; Nelson Jen; Junjie Chen; Hilary Yen; C-C Jay Kuo; Neil C Chi; Chih-Ming Ho; Rongsong Li; Tzung K Hsiai
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

4.  Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers.

Authors:  Ahmed A Abdelsameea; Noha A T Abbas; Samar M Abdel Raouf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-16       Impact factor: 3.000

5.  Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction.

Authors:  Jennifer Miao; Shi Huang; Yan Ru Su; Carrie A Lenneman; Meera Wright; Frank E Harrell; Douglas B Sawyer; Daniel J Lenihan
Journal:  Biomarkers       Date:  2018-08-17       Impact factor: 2.658

6.  Neuregulin-1β attenuates sepsis-induced diaphragm atrophy by activating the PI3K/Akt signaling pathway.

Authors:  Jin Wu; Hua Liu; Ting Chu; Peng Jiang; Shi-Tong Li
Journal:  J Muscle Res Cell Motil       Date:  2019-04-16       Impact factor: 2.698

Review 7.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 8.  Growth factor therapy for cardiac repair: an overview of recent advances and future directions.

Authors:  Samuel J White; James J H Chong
Journal:  Biophys Rev       Date:  2020-07-20

Review 9.  Neuregulin in cardiovascular development and disease.

Authors:  Oghenerukevwe Odiete; Michael F Hill; Douglas B Sawyer
Journal:  Circ Res       Date:  2012-10-26       Impact factor: 17.367

10.  Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling.

Authors:  Liangliang Zhou; Lanping Chen; Jing Wang; Yijun Deng
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.